Phase 2 Serplulimab Neoadjuvant Trial Now Active, Not Recruiting

On October 16, 2026, a registered clinical trial update was recorded for a study titled "Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction." The trial is listed as Phase 2 under identifier NCT06576921. Its current status is active, not recruiting, meaning enrollment is not currently open but the study is ongoing. The trial evaluates serplulimab administered together with chemotherapy as a neoadjuvant approach, meaning treatment given before primary surgical intervention. No results have been posted in connection with this status update, and no efficacy or safety outcomes are reported at this time. The update reflects only the trial's registration status as of the date noted. This brief does not characterize whether the treatment is effective or safe, as no outcome data accompanies this status change. Readers should note that substance p, referenced in connection with this listing, remains classified as an unapproved research compound and is not an approved therapeutic. Further updates to this trial's status, including any eventual results, would be expected to follow standard clinical trial reporting timelines. For additional background on this compound, see the linked compound overview.